While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...

This new technology utilizes data from the Dexcom G7 15 Day sensor to provide personalized insulin recommendations. Alongside this development, DexCom released its third-quarter earnings, reporting a ...

When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...

Dexcom G7 users have been complaining about a problem they term “goose necking” where the wire loops out of the hole on the sensor, causing the sensor to fail. Incoming CEO Jake Leach tells MD+DI the ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...